Trial Profile

Thorough ECG (QT) study of EVK-001 (metoclopramide nasal spray) in healthy volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metoclopramide (Primary)
Indications Diabetic gastroparesis
Focus Adverse reactions; Registrational
Sponsors Evoke Pharma

Most Recent Events

24 May 2016 According to Evoke Pharma media release, this study was designed in accordance with published FDA and ICH guidance on the clinical evaluation of QT/QTc interval prolongation and the proarrhythmic potential of non-cardiac drugs.
24 May 2016 Data from this study were presented at Digestive Disease Week (DDW) 2016, as per Evoke Pharma media release.
17 Feb 2016 According to an Evoke Pharma media release, results from this study will be presented at the Digestive Disease Week 2016.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com